Summary
The biliary excretion and apparent oral clearance of metoclopramide (MCL) were determined after oral administration of 1 mg MCL/kg body weight to 10 patients suffering from extrahepatic cholestasis with nasobiliary tube for drainage of the common bile duct. A bilioduodenal endoprosthesis was subsequently fitted in 6 of these patients, i.e. the enterohepatic circulation was restored, and the apparent oral clearance was re-determined.
Biliary excretion, comprising free MCL and the products of conjugation, accounted for less than 1% of the administered dose. In accordance with this, the median areas under the plasma concentration-time-curves AUC(0–15 h) in patients with intact and interrupted enterohepatic recirculation were of similar size. The pharmacokinetic values in patients with cholestasis (median apparent oral clearance 0.5 l·kg−1·h−1; median t1/2 4.5 h) were similar to those previously reported in patients with healthy liver function.
We conclude that it is not necessary to adjust single doses of MCL in patients recovering from obstructive jaundice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bateman DN (1983) Clinical pharmacokinetics of metoclopramide. Clin Pharmacokinet 8: 523–529
Hellenbrecht D, Saller R, Briemann L, Brinkmann C, Hellstern A, Hess H, Mitrou P, Achtert G, Brockmann P, Hausleiter HJ (1985) Vergleich der Pharmakokinetik von hochdosiertem Metoclopramid nach intravenöser und oraler Gabe zur Prophylaxe von Cisplatin-Erbrechen. Klin Wochenschr 63 [Suppl IV]: III-XXVI
Ritschel WA (1986) Handbook of basic pharmacokinetics, 3rd edn. Drug Intelligence Publications, Hamilton
Shepard TA, Reuning RH, Aaron LJ (1985) Estimation of area under the curve for drugs subject to enterohepatic cycling. J Pharmacokinet Biopharm 13: 589–608
Dobrinska MR (1989) Enterohepatic circulation of drugs. J Clin Pharmacol 29: 577–580
Saller R, Hellenbrecht D, Briemann L, Hellstern A, Hess H, Mitrou P, Hogdson M, Achtert G, Brockmann P, Hausleiter HP (1985) Metoclopramide kinetics at high-dose infusion rates for prevention of cisplatin-induced emesis. Clin Pharmacol Ther 37: 43–47
Hellstern A, Hildebrand M, Hümpel M, Hellenbrecht D, Saller R, Madetzki C (1990) Minimal biliary excretion and enterohepatic recirculation of lormetazepam in man as investigated by a new nasobiliary drainage technique. Int J Clin Pharmacol Ther Toxicol 28: 256–261
Ritschel WA, Adolph S, Denson DD (1990) Ion-trapping of meperidine: influence of antacid treatments on serum and gastric fluid concentrations. Meth Find Exp Clin Pharmacol 12: 47–51
Thureborn E (1961) Human hepatic bile. Composition changes due to altered enterohepatic circulation. Acta Chir Scand [Suppl] 303: 1–63
Meijer DKF, Weitering JG, Vermeer GA (1983) Pharmacokinetics of biliary excretion in man. V. Eur J Clin Pharmacol 24: 549–556
Carulli N, Manenti F, Ponz Leon de M, Ferrari A, Salvioli G, Gallo M (1972) Alteration of drug metabolism during cholestasis in man. Eur J Clin Invest 5: 455–462
Drew R, Priestley BG (1976) Hexobarbital sleeping time and drug metabolism in rats with ligated bile ducts — a lack of correlation. Biochem Pharmacol 25: 1659–1663
Knodell RG, Brooks DA, Allen RC, Kyner WT (1980) Alterations of phenobarbital and meperidine pharmacokinetics induced by bile duct ligation in the rat. J Pharmacol Exp Ther 215: 619–625
Richter E, Grün M, Zilly W, Brachtel D, Kühn AH (1972) Arzneimittelmetabolismus bei tierexperimenteller Cholestase. Verh Dtsch Ges Inn Med 78: 1402–1404
Hepner GW, Vesell ES, Lipton A, Harvey HA, Wilkinson GR, Schenker S (1977) Disposition of aminopyrine, antipyrine, diazepam and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. J Lab Clin Med 90: 440–456
Richter E, Breimer DD, Zilly W (1980) Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. Eur J Clin Pharmacol 17: 197–202
Wilkinson GR, Branch RA (1984) Effects of hepatic disease on clinical pharmacokinetics. In: Benet LZ, Massoud N, Gambertoglio JG (eds) Pharmacokinetic basis for drug treatment. Raven Press, New York, pp 49–61
Taylor WB, Bateman DN (1986) Oral bioavailability of high-dose metoclopramide. Eur J Clin Pharmacol 31: 41–44
Hellstern A, Hellenbrecht D, Saller R, Gatzen M, Achtert G, Brockmann P, Hausleiter HJ, Leuschner U (1986) Absolute bioavailability of metoclopramide given orally or by enema in patients with normal liver function or with cirrhosis of the liver. Arzneimittelforschung Drug Res 37: 733–736
Saller R, Hellstern A, Hellenbrecht D, Gatzen M, Siede W, Achtert G, Brockmann P, Dahmen W (1989) Quantification of the secretion of the basic drugs lidocaine and metoclopramide into the acidic gastric juice. Gastroenterology 96 [Suppl]: A 653
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hellstern, A., Hellenbrecht, D., Saller, R. et al. Minimal biliary excretion and enterohepatic recirculation of metoclopramide in patients with extrahepatic cholestasis. Eur J Clin Pharmacol 45, 415–418 (1993). https://doi.org/10.1007/BF00315511
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315511